Recombinant Human Vegf-A: Enhance Your Research with Quality Solutions

Alpha Lifetech Incorporation is proud to present our latest product, Recombinant Human Vegf-A. Our recombinant human VEGF-A is a highly purified, bioactive protein that has been manufactured using advanced technology to ensure maximum potency and effectiveness, Recombinant Human Vegf-A is a key protein involved in the regulation of blood vessel formation and has been extensively studied for its potential therapeutic applications in various medical fields including angiogenesis, vascular biology, and wound healing. Our product is produced under strict quality control measures to guarantee its purity, stability, and bioactivity, making it an ideal choice for research and development purposes, With Alpha Lifetech Incorporation's commitment to delivering high-quality products, you can trust that our Recombinant Human Vegf-A will meet your research needs and contribute to the advancement of scientific knowledge in the field of vascular biology and angiogenesis. We are excited to offer this innovative product to support your research endeavors and look forward to contributing to your success in the scientific community

Hot Selling Product

ALP64522-Recombinant Human BTLA/CD272 Protein, mFc Tag

ALP64527-Recombinant Human Biotinylated FGL1 Protein, Fc Tag, Avi Tag

ALP64550-Recombinant Human ILT3/CD85k/LILRB4 Protein, His Tag

ALP64505-Recombinant Human CD24 Protein, mFc Tag

ALP64506-Recombinant Human Biotinylated CD28 Protein, Fc Tag, Avi Tag

ALP64509-Recombinant Human Siglec-10 Protein, mFc Tag

Methods To Recombinant Human Vegf-A Delivers Unmatched Quality Factory-Direct Excellence

In the rapidly advancing field of biotechnology, the demand for high-quality recombinant human proteins is ever-growing. Alpha Lifetech Inc. stands at the forefront of this industry, offering unmatched quality with our recombinant human VEGF-A products. Founded by a team of experienced scientists specializing in membrane protein production and monoclonal development, we have established a reputation for excellence. With a portfolio that includes nearly 10,000 premium reagents, cytokines, and drug target antibodies, our factory-direct offerings ensure that global buyers receive not only superior quality but also reliable and consistent results. Our methods for producing recombinant human VEGF-A leverage cutting-edge technology and rigorous quality control processes. This enables us to deliver products that are exceptionally pure and biologically active, meeting the specific needs of researchers and developers worldwide. By providing direct access to our world-class reagents, we eliminate intermediaries and reduce costs, benefitting our customers while maintaining the highest standards of quality. Trust Alpha Lifetech Inc. to support your research and development efforts with our unparalleled selection of high-quality recombinant proteins, tailored for success in your projects.

Methods To Recombinant Human Vegf-A Delivers Unmatched Quality Factory-Direct Excellence

Method	Description	Quality Metrics	Cost Efficiency
Recombinant DNA Technology	Utilizes molecular cloning for yielding high-purity VEGF-A.	Purity: > 95%	Cost per mg: $50
Cell-Free Protein Synthesis	Fast-track production without living cells, reducing contamination.	Yield: 1 mg/mL	Cost per mg: $75
Transgenic Animal Models	Utilizes genetically modified animals to produce human VEGF-A.	Yield: 5 g/L	Cost per mg: $150
Microbial Fermentation	Employs bacteria for high-volume production of VEGF-A.	Purity: > 90%	Cost per mg: $30
Mammalian Cell Culture	Standard for post-translational modifications, producing authentic human VEGF-A.	Purity: > 98%	Cost per mg: $100

Comparative Analysis of Recombinant Human VEGF-A Production Methods

The production of Recombinant Human VEGF-A can be approached through various methods, each yielding different amounts of the target protein. Method A achieved a yield of 150 mg/L, while Method B outperformed others with 200 mg/L. Method C resulted in a lower yield of 120 mg/L, whereas Method D provided a satisfactory 180 mg/L. The analysis of these methods highlights the significant variability in production efficiency, underscoring the importance of selecting optimal production techniques to maximize yields in the development of therapeutic proteins.